Genentech Patient Foundation Responds to NHF-HFA Letter
On September 24, 2019, NHF and HFA sent a letter to Genentech and Medvantx regarding the shipment of incorrect length injection needles to patients who receive Hemlibra through the Genentech Patient Foundation. Genentech responded to our inquiries by letter dated September 25, 2019. You can read Genentech’s response here.
NHF and HFA will update the bleeding disorders community as any further information develops.
Please note that NHF and HFA do not recommend, endorse or make any representation about the efficacy, appropriateness or suitability of any specific products, treatments, or opinions. If you have any questions or concerns about your medical treatment, please consult your physician.